Emergent Biosolutions Sees Unusually Large Options Volume (NYSE:EBS)

Emergent Biosolutions Inc (NYSE:EBS) was the target of some unusual options trading on Friday. Investors acquired 2,283 call options on the stock. This is an increase of 571% compared to the typical volume of 340 call options.

In other Emergent Biosolutions news, Director Zsolt Harsanyi sold 4,940 shares of the stock in a transaction on Monday, May 11th. The stock was sold at an average price of $81.99, for a total transaction of $405,030.60. Following the completion of the transaction, the director now directly owns 24,933 shares of the company’s stock, valued at $2,044,256.67. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Ronald Richard sold 6,572 shares of the stock in a transaction on Wednesday, June 3rd. The shares were sold at an average price of $87.51, for a total value of $575,115.72. Following the transaction, the director now directly owns 4,269 shares of the company’s stock, valued at $373,580.19. The disclosure for this sale can be found here. Over the last three months, insiders have sold 19,887 shares of company stock valued at $1,651,738. 14.10% of the stock is owned by corporate insiders.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Copper Rock Capital Partners LLC lifted its stake in Emergent Biosolutions by 4,355.7% during the second quarter. Copper Rock Capital Partners LLC now owns 8,772,689 shares of the biopharmaceutical company’s stock worth $646,750,000 after purchasing an additional 8,575,801 shares during the last quarter. Norges Bank bought a new stake in Emergent Biosolutions in the 4th quarter worth approximately $30,029,000. Invesco Ltd. lifted its position in Emergent Biosolutions by 49.8% in the 1st quarter. Invesco Ltd. now owns 912,224 shares of the biopharmaceutical company’s stock worth $52,781,000 after buying an additional 303,427 shares during the last quarter. The Manufacturers Life Insurance Company lifted its position in Emergent Biosolutions by 46.7% in the 1st quarter. The Manufacturers Life Insurance Company now owns 902,317 shares of the biopharmaceutical company’s stock worth $52,208,000 after buying an additional 287,074 shares during the last quarter. Finally, Loomis Sayles & Co. L P lifted its position in Emergent Biosolutions by 147.9% in the 1st quarter. Loomis Sayles & Co. L P now owns 442,346 shares of the biopharmaceutical company’s stock worth $25,594,000 after buying an additional 263,898 shares during the last quarter. Institutional investors and hedge funds own 85.52% of the company’s stock.

Several equities research analysts have issued reports on EBS shares. Argus increased their target price on Emergent Biosolutions from $67.00 to $90.00 and gave the stock a “buy” rating in a research report on Wednesday, May 6th. Zacks Investment Research downgraded Emergent Biosolutions from a “hold” rating to a “sell” rating and set a $89.00 target price on the stock. in a research report on Wednesday, May 27th. Cantor Fitzgerald increased their target price on Emergent Biosolutions from $85.00 to $110.00 and gave the stock an “overweight” rating in a research report on Friday, July 17th. Wells Fargo & Co increased their target price on Emergent Biosolutions from $85.00 to $93.00 and gave the stock an “overweight” rating in a research report on Thursday, July 2nd. Finally, Chardan Capital increased their target price on Emergent Biosolutions from $86.00 to $112.00 and gave the stock a “buy” rating in a research report on Friday. One analyst has rated the stock with a sell rating, two have issued a hold rating and six have given a buy rating to the stock. Emergent Biosolutions has a consensus rating of “Buy” and an average price target of $90.00.

Shares of EBS stock opened at $111.24 on Friday. The company has a debt-to-equity ratio of 0.71, a quick ratio of 1.83 and a current ratio of 3.03. Emergent Biosolutions has a 52-week low of $39.11 and a 52-week high of $114.13. The company has a market capitalization of $5.83 billion, a PE ratio of 34.65 and a beta of 1.27. The business’s fifty day moving average is $84.58 and its 200 day moving average is $70.75.

Emergent Biosolutions (NYSE:EBS) last issued its quarterly earnings data on Thursday, July 30th. The biopharmaceutical company reported $1.98 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.53 by $1.45. Emergent Biosolutions had a return on equity of 23.64% and a net margin of 13.52%. The company had revenue of $394.70 million for the quarter. On average, sell-side analysts forecast that Emergent Biosolutions will post 4.23 EPS for the current fiscal year.

About Emergent Biosolutions

Emergent BioSolutions Inc, a life sciences company, focuses on the provision of specialty products for civilian and military populations that address accidental, intentional, and naturally occurring public health threats (PHTs). Its products address PHTs, including chemical, biological, radiological, nuclear, and explosives; emerging infectious diseases; travelers' diseases; and opioids.

Recommended Story: Diversification in Investing

Receive News & Ratings for Emergent Biosolutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Emergent Biosolutions and related companies with MarketBeat.com's FREE daily email newsletter.